Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | PYGB | P11216 | 2/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
| ▸ | PYGM | P11217 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401860 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL4557921 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL9309804 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL9699515 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL5551957 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL25366499 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL19326770 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL2381492 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL22409570 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM | |
| SCHEMBL9060748 | 1.00 | GAA (0.37) | GAAPYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2026-02-17 | — | — | US | claimed |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-12-26 | — | — | US | claimed |
| EP-4397374-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2024-07-10 | — | — | EP | claimed |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2022-11-17 | — | — | US | claimed |
| EP-2710031-B9 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-2710031-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2017-09-13 | — | — | EP | claimed |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250313604-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250281450-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | MEDERIS DIABETES LLC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250136656-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12257229-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | SPITFIRE PHARMA LLC (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4506017-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | Mederis Diabetes, LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-12-26 | — | — | US | disclosed |
| CN-117582516-A | Improved peptide drugs against insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3155017-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117180445-A | Improved peptide drugs against insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230218564-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | MEDERIS DIABETES LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11541028-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | ALTIMMUNE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2022-11-17 | — | — | US | disclosed |
| WO-2022178366-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | SPITFIRE PHARMA LLC (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, INSR | GAA 2546/4885PYGB 2276/4885PYGL 689/4885 |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | GAA 479/4885PYGB 719/4885PYGL 208/4885 |
| US-12257229-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | GLP1R, IAPP, GPR119 | GAA 1170/4885PYGB 1621/4885PYGL 148/4885 |
| US-20250281450-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | GLP1R, IAPP, GPR119 | GAA 1170/4885PYGB 1621/4885PYGL 148/4885 |
| US-20230218564-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | GLP1R, IAPP, GPR119 | GAA 1170/4885PYGB 1621/4885PYGL 148/4885 |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | GAA 479/4885PYGB 719/4885PYGL 208/4885 |
| US-20250136656-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | GAA 479/4885PYGB 719/4885PYGL 208/4885 |
| US-20250313604-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | GAA 479/4885PYGB 719/4885PYGL 208/4885 |
| US-11541028-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | GLP1R, IAPP, GPR119 | GAA 1170/4885PYGB 1621/4885PYGL 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.